Eli Lilly

The funding is being provided by Genome Canada, as well as various Canadian provinces, businesses, and research institutes.

A CIO panel discussed why genomics IT is prepared for new security challenges and why organizations need to step up staff training and retention strategies.

The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.

The project team is driving the development of practice guidelines because sample handling and quality are often not up to the mark.    

Thermo Fisher Scientific, Illumina, Eli Lilly, Celgene, and Roche/Genentech have committed their expertise and funding to build a lung cancer registry.

In the study, called TAPUR, ASCO will give cancer patients who are out of treatment options off-label drugs based on their genomic data and record their outcomes in a registry.

Lilly decided to stop developing the drug in 2012, but Denovo thinks it can identify a subset of genetically defined patients that can benefit from the drug.

NEW YORK (GenomeWeb) — Biomarker development firm Denovo Biopharma has acquired the late-stage oncology drug enzastaurin from Eli Lilly and Company, and plans to use its genotyping platform to uncover a genomic marker or markers that can support new clinical trials advancing the drug for a genomi

NEW YORK (GenomeWeb) — As part of its quest to become a catch-all provider of tools and technologies for molecular diagnostic and especially companion diagnostic development, Qiagen has added another molecular analysis platform to its portfolio.

Originally published June 3.
NEW YORK (GenomeWeb) – Data from two large studies that tested the efficacy of widely used targeted drugs in molecularly defined breast cancer and colorectal cancer populations failed to show superiority of one therapeutic strategy over another.


Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.